Previous close | 5.37 |
Open | 5.36 |
Bid | 0.00 x 3000 |
Ask | 0.00 x 3000 |
Day's range | 4.93 - 5.62 |
52-week range | 2.19 - 12.89 |
Volume | |
Avg. volume | 3,004,106 |
Market cap | 637.747M |
Beta (5Y monthly) | 1.33 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.29 |
Earnings date | 01 Nov 2022 - 07 Nov 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 15.08 |
The average of price targets set by Wall Street analysts indicates a potential upside of 90.6% in Heron Therapeutics (HRTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -10% and 11.98%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shareholders should be happy to see the share price up 12% in the last month...